We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+15.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$214M
AUM Growth
+$8.02M
Cap. Flow
-$22.7M
Cap. Flow %
-10.61%
Top 10 Hldgs %
48%
Holding
89
New
17
Increased
13
Reduced
25
Closed
14

Top Buys

Rank Stock Value
1
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$3.38M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.82M
3
KURA icon
Kura Oncology
KURA
+$1.91M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.63M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$1.38M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.44M
2
ARGX icon
argenx
ARGX
+$2.88M
3
PODD icon
Insulet
PODD
+$2.82M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.72M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 85.47%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCNI
76
Scinai Immunotherapeutics
SCNI
$1.43M
– –
-34
Closed -$18K
SCPH
77
DELISTED
scPharmaceuticals
SCPH
– –
-55,844
Closed -$692K
SPRO icon
78
Spero Therapeutics
SPRO
$69.5M
– –
-29,544
Closed -$421K
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.3B
– –
-60,000
Closed -$298K
MTVA
80
MetaVia Inc
MTVA
$7.44M
– –
-2
Closed -$651K
KA
81
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,908
Closed -$1.27M
SRRA
82
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,999
Closed -$166K
CMTA
83
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-105,000
Closed -$1.59M
CGNT
84
DELISTED
Cogentix Medical, Inc.
CGNT
– –
-310,382
Closed -$1.2M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, DAFNA Capital Management held 89 positions worth $214M, up 3.9% from $206M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q2 2018, closing 14 positions and reducing 25 holdings. Its most notable exit was Insulet, an estimated $2.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Yarrow Bioscience, Inc. Common Stock worth $2.53M.

  • DAFNA Capital Management's largest Q2 2018 buy was Yarrow Bioscience, Inc. Common Stock: 87 shares worth $2.53M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2018, an estimated $1.91M increase.
  • DAFNA Capital Management's biggest Q2 2018 reduction was Loxo Oncology, Inc, cutting an estimated $3.44M.
  • DAFNA Capital Management fully exited Insulet in Q2 2018, selling an estimated $2.82M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $214M portfolio in Q2 2018.
  • DAFNA Capital Management opened 17 new positions and closed 14 in Q2 2018.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $214M.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.